Reviewer’s report

Title: PRE-TREATMENT CLINICAL FEATURES IN CENTRAL RETINAL VEIN OCCLUSION THAT PREDICT VISUAL OUTCOME FOLLOWING INTRAVITREAL RANIBIZUMAB

Version: 0 Date: 02 Nov 2017

Reviewer: Sylvia Nghiêm-Buffet

Reviewer’s report:

Here are some comments for the authors:

Methods need to be further described:

- description of the regimen of treatment (PRN or monthly treatment ?)

- Naive traitement patients ? You need to specify clearly as some patients had a first ranibizumab treatment several months after the time from presentation

Results:

Can you specify the mean number of ranibizumab injections during the 12 months of follow-up? That could explain the inefficiency of ranibizumab

Discussion:

* Discussion need to be reorganized and shortened.

* You should discuss about the pre-treatment clinical features identified in your serie as predictive factors of the final visual outcome and you should refere to others articles already published on this subject.

* You don't discuss why ranibizumab is not effective in your serie.

* Page 8 ligne 12 : You say that « the treatment benefit in ischaemic CRVO has not been proven as patients with significant baseline retinal ischaemia were excluded in the landmark studies. » That is true for CRUISE and BRAVO but not for GALILEO and COPERNICUS. In Galileo and Copernicus, RAPD were not excluded and sub-division of patients (Perfused, Non perfused, Indeterminable) was defined by >/< 10 Disc area of retinal non perfusion on FFA. So these two studies included severe ischaemic CRVO.

* You want to stop classifying patients into ischaemic and not ischaemic group and to focus on looking at clinical features in CRVO that predict poorer visual outcome from
anti-VEGF therapy but finally poorer pre treatment VA and CWS are ischaemia indicators already identified in previous studies

Finally you should reorganize and shortern your discussion in that way:

* Efficiency of anti-VEGF in RVO
* Difficulty to identify ischaemia and the different technics already known
* Importance to distinguish macular ischemia from global ischemia (CRYSTAL)
* Discussion of predictive factors you identified in your study and comparison with previous study
* Discussion of inefficiency of ranibizumab in your serie
* Discussion of the necessity or not of treatment in ischaemic CRVO
* Conclude with the importance to identify predictive factors of visual outcome to initiate treatment of CRVO

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

No

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

No

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English
Please indicate the quality of language in the manuscript:
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal